Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

History

Imago BioSciences was founded in 2017 by a team of scientists and entrepreneurs to help bridge the gap between research and commercial drug discovery. Their mission is to enable investigators to more quickly, efficiently and cost-effectively address the many challenges facing them during preclinical drug development. Imago BioSciences uses a wide range of technologies, including 3D cell culture systems, synthetic biology, computational biology, molecular biology and precision engineering.

Mission

To facilitate and accelerate drug discovery by providing unique capabilities and technological solutions to the life science community.

Vision

To become the leading supplier of 3D cell-based drug screening and custom genetic engineering solutions to the pharmaceutical and biotech industries.

Key Team

Ms. Hsiangyi Chiang (Sr. VP of Fin. & Principal Accounting Officer)

Dr. Amy E. Tapper Ph.D. (Chief of Technical Operations)

Ms. Jennifer Peppe (Global Head of Clinical Operations)

Recognition and Awards

Imago BioSciences was recently named a 2018 Top 10 Biotech Innovator by the Association for Laboratory Automation. They also won the Golden Goose Award for their work on a 3D cell culture system for drug screening.